{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:14:35Z","timestamp":1768878875882,"version":"3.49.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.gastrohep.2017.05.008","type":"journal-article","created":{"date-parts":[[2017,7,23]],"date-time":"2017-07-23T00:30:17Z","timestamp":1500769817000},"page":"629-640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recomendaciones de uso de everolimus en el trasplante hep\u00e1tico"],"prefix":"10.1016","volume":"40","author":[{"given":"Angel","family":"Rub\u00edn Su\u00e1rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itxarone","family":"Bilbao Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Fern\u00e1ndez-Castroagudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Pons Mi\u00f1ano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Salcedo Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evaristo","family":"Varo P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"Prieto Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2017.05.008_bib0370","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0375","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.gastrohep.2017.05.008_bib0380","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lt.22410","article-title":"Present state of immunosuppressive therapy in liver transplant recipients","volume":"17","author":"Wiesner","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0385","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/ajt.13151","article-title":"Evolving perspectives of mTOR complexes in immunity and transplantation","volume":"15","author":"Fantus","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0390","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1472-8206.2011.00957.x","article-title":"Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: A differential effect between cyclosporine and tacrolimus","volume":"26","author":"Lamoureux","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0395","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0400","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/lt.20707","article-title":"Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36-month results","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0405","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/j.1600-6143.2010.03128.x","article-title":"Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function","volume":"10","author":"Masetti","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0410","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT","volume":"12","author":"Fischer","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0415","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ajt.12615","article-title":"Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation","volume":"14","author":"Sterneck","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0420","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/ctr.12744","article-title":"Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study","volume":"30","author":"Sterneck","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0425","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0430","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/ajt.12280","article-title":"Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study","volume":"13","author":"Saliba","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0435","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0000000000000555","article-title":"Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: Follow-up results from a randomized, multicenter study","volume":"99","author":"Fischer","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0440","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1097\/00007890-200112270-00012","article-title":"End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment","volume":"72","author":"Gonwa","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0445","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0041-1345(03)00642-0","article-title":"Chronic renal dysfunction after liver transplantation in adult patients: Prevalence, risk factors, and impact on mortality","volume":"35","author":"Moreno","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0450","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5500\/wjt.v5.i1.26","article-title":"Underestimation of chronic renal dysfunction after liver transplantation: ICEBERG study","volume":"5","author":"Varo","year":"2015","journal-title":"World J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0455","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/j.ackd.2015.06.001","article-title":"Chronic kidney disease and related long-term complications after liver transplantation","volume":"22","author":"Sharma","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0460","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/TP.0b013e3182384aff","article-title":"Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation","volume":"92","author":"Cantarovich","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0465","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.dld.2008.09.018","article-title":"Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study","volume":"41","author":"Burra","year":"2009","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0470","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2014.03.034","article-title":"Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate","volume":"61","author":"Allen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0475","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0480","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.transproceed.2006.10.054","article-title":"Renal disease burden following liver transplantation","volume":"38","author":"Kim","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0485","first-page":"13","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0490","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0495","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial","volume":"15","author":"De Simone","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0500","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/lt.21920","article-title":"Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction","volume":"15","author":"Castroagudin","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0505","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/lt.22292","article-title":"Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis","volume":"17","author":"Saliba","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0510","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/lt.24172","article-title":"Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain","volume":"21","author":"Bilbao","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0515","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0520","unstructured":"European Liver Transplant Registry. Volume 2016."},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0525","unstructured":"ONT. Memoria trasplante hep\u00e1tico 2015. Volume 2016, 2015."},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0530","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0535","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/lt.21999","article-title":"Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States","volume":"16","author":"Pomfret","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0540","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/archsurg.2007.39","article-title":"Recurrence of hepatocellular carcinoma following liver transplantation: A review of preoperative and postoperative prognostic indicators","volume":"143","author":"Zimmerman","year":"2008","journal-title":"Arch Surg"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0545","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0550","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jhep.2013.11.031","article-title":"Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends","volume":"60","author":"Matter","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0555","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.trre.2015.02.003","article-title":"mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?","volume":"29","author":"Duvoux","year":"2015","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0560","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3748\/wjg.v11.i10.1420","article-title":"Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth","volume":"11","author":"Schumacher","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0565","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MOT.0000000000000069","article-title":"Liver transplantation: Immunosuppression and oncology","volume":"19","author":"Rodriguez-Peralvarez","year":"2014","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0570","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/SLA.0b013e3181896278","article-title":"Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: Reassessment of risk factors for tumor recurrence","volume":"248","author":"Vivarelli","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0575","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/lt.22441","article-title":"Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis","volume":"18","author":"Liang","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0580","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/apt.12185","article-title":"Meta-analysis: Recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma","volume":"37","author":"Menon","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0585","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/tri.12372","article-title":"Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: A systematic review","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0590","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A Randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0595","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/lt.24395","article-title":"Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma","volume":"22","author":"Yanik","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0600","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/lt.22434","article-title":"Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation","volume":"18","author":"Gomez-Martin","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0605","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/tri.12477","article-title":"Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant","volume":"28","author":"Mancuso","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0610","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.transproceed.2013.10.035","article-title":"Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation","volume":"46","author":"De Simone","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0615","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/lt.23722","article-title":"Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection","volume":"19","author":"Schrem","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0620","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/ajt.12384","article-title":"Twenty-year longitudinal follow-up after orthotopic liver transplantation: A single-center experience of 313 consecutive cases","volume":"13","author":"Schoening","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0625","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1478-3231.2010.02303.x","article-title":"Risk factors and incidence of de novo malignancy in liver transplant recipients: A systematic review","volume":"30","author":"Chak","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0630","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1600-6143.2004.00380.x","article-title":"De novo internal neoplasms after liver transplantation: Increased risk and aggressive behavior in recent years?","volume":"4","author":"Benlloch","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0635","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.080068597","article-title":"The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders","volume":"97","author":"Majewski","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0640","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5500\/wjt.v4.i2.122","article-title":"Multiple indications for everolimus after liver transplantation in current clinical practice","volume":"4","author":"Bilbao","year":"2014","journal-title":"World J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0645","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.tp.0000280549.93403.dd","article-title":"Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms","volume":"84","author":"Gomez-Camarero","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0650","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/ctr.12430","article-title":"Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease","volume":"28","author":"Thimonier","year":"2014","journal-title":"Clin Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0655","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.transproceed.2009.06.087","article-title":"Indications and management of everolimus after liver transplantation","volume":"41","author":"Bilbao","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0660","first-page":"115","article-title":"Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience","volume":"58","author":"Jimenez-Romero","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0665","unstructured":"AEMPS. Ficha T\u00e9cnica Certican."},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0670","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00007890-199707150-00007","article-title":"SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine","volume":"64","author":"Schuurman","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0675","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.transproceed.2006.10.092","article-title":"Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus","volume":"38","author":"Kovarik","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0680","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.trre.2015.12.003","article-title":"Use of everolimus in liver transplantation: The French experience","volume":"30","author":"Dumortier","year":"2016","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0685","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.trre.2010.01.005","article-title":"Clinical recommendations for the use of everolimus in heart transplantation","volume":"24","author":"Manito","year":"2010","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0690","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/TP.0b013e31825b411c","article-title":"A comprehensive review of everolimus clinical reports: A new mammalian target of rapamycin inhibitor","volume":"94","author":"Gurk-Turner","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0695","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40259-013-0041-6","article-title":"Everolimus: A guide to its use in liver transplantation","volume":"27","author":"Keating","year":"2013","journal-title":"BioDrugs: Clinical immunotherapeutics, biopharmaceuticals and gene therapy"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0700","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/liv.12133","article-title":"Calcineurin inhibitors in liver transplantation-still champions or threatened by serious competitors?","volume":"33","author":"Beckebaum","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0705","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trre.2012.11.001","article-title":"Recommendations on the use of everolimus in lung transplantation","volume":"27","author":"De Pablo","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0710","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0715","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1432-2277.2008.00768.x","article-title":"Conversion to everolimus monotherapy in maintenance liver transplantation: Feasibility, safety, and impact on renal function","volume":"22","author":"De Simone","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0720","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.transproceed.2005.09.127","article-title":"Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: A multicenter study","volume":"37","author":"Ruiz","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0725","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-6143.2004.00590.x","article-title":"Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction","volume":"4","author":"Diekmann","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gastrohep.2017.05.008_bib0730","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trre.2014.08.003","article-title":"mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?","volume":"29","author":"Holdaas","year":"2015","journal-title":"Transplant Rev (Orlando)"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570517301310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570517301310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T08:14:12Z","timestamp":1569917652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570517301310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0210570517301310"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2017.05.008","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones de uso de everolimus en el trasplante hep\u00e1tico","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2017.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U., AEEH y AEG. All rights reserved.","name":"copyright","label":"Copyright"}]}}